Meeting
2020 ASCO Virtual Scientific Program
Safety of 177Lu‑DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program.
Authors
Martin S. Auerbach
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA
Martin S. Auerbach , Edward M. Wolin , Val Nassiri , Per Broberg , Ghassan El-Haddad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT02705313
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4604)
DOI
10.1200/JCO.2020.38.15_suppl.4604
Abstract #
4604
Poster Bd #
212
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2013 ASCO Annual Meeting
Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).
First Author: Oliver Edgar Bechter
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
First Author: Ting Han